Common reactions may include pain, redness, or irritation at the injection site, mild diarrhea, nausea, itching, headache, dizziness, or a general feeling of swelling
In 2019, an FDA advisory committee voted that the benefit conferred by quizartinib did not outweigh the safety risks
In such cases, 1.5 to 2-inch needles are mandated
Aged mice were divided into control and treatment groups, with the latter receiving intraperitoneal injections of FOXO4-DRI at doses of 0.5 mg/mL and 5 mg/kg every other day for 30 days, while controls received PBS
The Cybersecurity Maturity Model Certification (CMMC) 2.0 final rule was published on December 16, 2024, starting the clock on a 60 day countdown toward implementation requirements